Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Results of Operations and Financial Condition

share with twitter share with LinkedIn share with facebook
share via e-mail
01/11/2017 | 11:02am CET

NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Results of Operations and Financial Condition


Results of Operations and Financial

Please see the disclosure relating to the estimated cash and
investments in market securities of Nektar Therapeutics, a
Delaware corporation (the Company), set forth under Item 8.01
Other Events of this Current Report on Form 8-K, which is
incorporated by reference into this Item 2.02.

Item8.01 Other Events.

On January 5, 2017, the Company announced that President and
Chief Executive Officer, Howard W. Robin, will make a
presentation at the upcoming 35th Annual J.P. Morgan Healthcare
Conference in San Francisco at the Westin St. Francis Hotel on
Tuesday, January 10, 2017, at 2:00 p.m. Pacific time.The
presentation will be accessible via a Webcast through a link
posted on the Investors, Investor Events section of the Nektar
website: http://www.nektar.com. In addition, the Company will
webcast the QA breakout session immediately following its
presentation at 2:30 p.m. Pacific Time. This Webcast will be
available for replay until February 17, 2017.

As part of the presentation, Mr.Robin intends to announce that,
based upon the Companys preliminary estimates, as of December31,
2016, the Company had cash and investments in marketable
securities of approximately $389 million.This financial
information has been prepared by and is the responsibility of the
Companys management and has not been audited by the Companys
independent registered public accounting firm. Accordingly, the
Companys independent registered public accounting firm does not
express an opinion on or provide any other form of assurance with
respect to this preliminary data. This financial information is
subject to the completion of the Companys year-end financial
closing procedures, the preparation of the Companys consolidated
financial statements, and the completion of the audit of the
Companys consolidated financial statements as of and for the year
ended December31, 2016, and the Companys actual results may
differ from these estimates.

Mr. Robin also expects to present information, including making
certain forward-looking statements, regarding the potential
future royalty revenues from the Companys partner collaboration
agreements over the next several years, pre-clinical and clinical
development results and the progress and potential for the
Companys proprietary drug development programs, the planned start
date time frames for future clinical trials of the Companys
programs (NKTR-214, NKTR-358, NKTR-255, and NKTR-102), the timing
and availability of future clinical results and regulatory
decisions of the Companys programs (NKTR-181,
ONZEALDTM, NKTR-214, NKTR-358, Ciprofloxacin Dry
Powder for Inhalation, Amikacin Inhale, and
ADYNOVATETM), the potential for submitting a New Drug
Application (NDA) on an accelerated basis to the Food and Drug
Administration (FDA) in the event there is a positive outcome
from the ongoing blinded Phase 3 clinical study for NKTR-181, and
certain other future events.This information and these
forward-looking statements involve substantial risks and
uncertainties including but not limited to:

The Companys proprietary drug candidates and those of its
collaboration partners, including NKTR-181, NKTR-214,
ONZEALDTM, NKTR-358, NKTR-255, Ciprofloxacin Dry
Powder for Inhalation and Amikacin Inhale, are still in
clinical development and the risk of failure remains high and
can unexpectedly occur at any time prior to regulatory
approval due to lack of efficacy, safety issues,
manufacturing challenges or other factors that can impact
drug development.
The estimated timing of the commencement of and completion of
clinical trials and the subsequent availability of clinical
trial results may be delayed or unsuccessful due to
additional time being required to measure certain clinical
trial end points, slower than anticipated patient accrual,
regulatory delays, clinical trial design (and regulatory
concurrence for design), manufacturing challenges, changing
standards of care or unexpected clinical outcomes.
The time required for obtaining regulatory decisions is
uncertain and difficult to predict. The FDA and other foreign
regulatory authorities have substantial discretion, at any
phase of development, to terminate clinical studies, require
additional clinical development or other testing, delay or
withhold registration and marketing approval and mandate
product withdrawals, including recalls.
The royalty revenue potential from the Companys collaboration
partners, including the revenue from the sales of ADYNOVATE
and MOVANTIK, is based on managements current estimates only
(and in some cases based onthird party data that has not been
independently verified by the Company) and actual royalty
revenue may differ materially and adversely. The Company
relies solely on our collaboration partners to market and
sell these products. The Company has very little control over
the timing and level of resources that our collaboration
partners dedicate to commercial marketing efforts such as the
amount of investment in sales and marketing personnel,
general marketing campaigns, direct-to-consumer advertising,
product sampling, pricing agreements and rebate strategies
with government and private payers, manufacturing and supply
of drug product, and other marketing and selling activities
that need to be undertaken and well executed for a drug to
have the potential to achieve commercial success.
The Companys patent applications for its proprietary or
partner product candidates may not issue, patents that have
issued may not be enforceable, or additional intellectual
property licenses from third parties may be required in the
The outcome of any existing or future intellectual property
or other litigation related to the Companys proprietary
product candidates or partner product candidates where the
Company has indemnification responsibility is unpredictable
and could have a material adverse effect on our business,
results of operations and financial condition.

The market sizes for the Companys proprietary and partnered
product programs are based on managements current estimates
only (and in some cases based onthird party data that has not
been independently verified by the Company) and actual market
sizes may differ materially and adversely.
Other important risks and uncertainties set forth in the
Companys Quarterly Report on Form 10-Q filed with the SEC on
November 4, 2016 for the quarter ended September 30, 2016.

Actual results could differ materially from the forward-looking
statements and the Company undertakes no obligation to update
forward-looking statements, whether as a result of new
information, future events or otherwise.

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company’s drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection). NEKTAR THERAPEUTICS (NASDAQ:NKTR) Recent Trading Information
NEKTAR THERAPEUTICS (NASDAQ:NKTR) closed its last trading session down -0.13 at 13.51 with 688,984 shares trading hands.

The post NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Results of Operations and Financial Condition appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
01/11 NEKTAR THERAPEUTICS (NASDAQ : NKTR) Files An 8-K Results of Operations and Finan..
01/10 NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Other Event..
01/05 NEKTAR THERAPEUTICS : ' President and CEO, Howard W. Robin, To Present at the 35..
2016 NEKTAR THERAPEUTICS : Shire announces FDA approval of ADYNOVATE for use in Child..
2016 NEKTAR THERAPEUTICS : Shire Announces FDA Approval of Adynovate® for use in Chil..
2016 NEKTAR THERAPEUTICS : Presents New Clinical Data from Ongoing Phase 1 Dose-Escal..
2016 NEKTAR THERAPEUTICS : to Present at Jefferies 2016 Global Healthcare Conference ..
2016 NEKTAR THERAPEUTICS : Presents New Clinical Data from Ongoing Phase 1 Dose-Escal..
2016 NEKTAR THERAPEUTICS : Other Events (form 8-K)
2016 NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/11 Nektar Therapeutics (NKTR) Presents At 35th Annual J.P. Morgan Healthcare Con..
2016 Piper's 17 biopharma surprises for 17
2016 UPCOMING EVENTS : Achaogen's Antibiotic; Nektar Tries Out Its Opioid (Again)
2016 Nektar Therapeutics Is Attractive Ahead Of Multiple Catalysts
2016 Nektar Therapeutics' (NKTR) CEO Howard Robin on Q3 2016 Results - Earnings Ca..
Financials ($)
Sales 2016 169 M
EBIT 2016 -112 M
Net income 2016 -149 M
Debt 2016 109 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 11,8x
EV / Sales 2017 10,1x
Capitalization 1 881 M
More Financials
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 8
Average target price 20,1 $
Spread / Average Target 64%
Consensus details
EPS Revisions
More Estimates Revisions
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 597
LONZA GROUP AG4.14%9 598
ALKERMES PLC-1.84%8 292
More Results